Relevant bibliographies by topics / Non-small cell lung cancer

Academic literature on the topic 'Non-small cell lung cancer'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 June 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Non-small cell lung cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Non-small cell lung cancer"

1

Cheng, Wenhan, M. D, MS c, Eldon Brown, MS c, Matt Gorman, B. S, Timothy Babushok, M. D, and PH D. "Immune Suppression Therapy in Aplastic Anemia Secondary to Atezolizumab in a Patient With Stage IV Non-Small Cell Lung Cancer." International Journal of Medical Reviews and Case Reports 4, Reports in Clinical Medicine and (2020): 1. http://dx.doi.org/10.5455/ijmrcr.atezolizumab-non-small-cell-lung-cancer.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hellriegel, H. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Klaus-Peter, K. "ADVANCED NON-SMALL-CELL LUNG CANCER. THE SIGNIFICANCE OF PERSONALIZED THERAPY." Siberian Medical Review, no. 6 (2017): 6–12. http://dx.doi.org/10.20333/2500136-2017-6-6-12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

_, _. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 6, no. 3 (March 2008): 228. http://dx.doi.org/10.6004/jnccn.2008.0021.

Full text
Abstract:
Lung cancer is the leading cause of cancer-related death in both men and women in the United States. An estimated 213,380 new cases (114,760 men and 98,620 women) of lung and bronchus cancer will be diagnosed in 2007, and 160,390 deaths (89,510 in men, 70,880 in women) are estimated to occur because of the disease. Non-small cell lung cancer (NSCLC) accounts for 80% to 85% of all lung cancer cases and includes 3 major types: (1) adenocarcinoma; (2) squamous cell (epidermoid) carcinoma; and (3) large-cell carcinoma. Adenocarcinoma is the most common type of lung cancer seen in the United States and is also the most frequently occurring cell type in nonsmokers. Important updates to the 2008 guidelines on NSCLC include the addition of tables on drugs and dosing information on chemotherapy regimens for adjuvant therapy. For the most recent version of the guidelines, please visit NCCN.org
APA, Harvard, Vancouver, ISO, and other styles
5

Skřičková, Jana, Bohdan Kadlec, and Ondřej Venclíček. "Non-small cell lung cancer." Vnitřní lékařství 63, no. 11 (November 1, 2017): 861–74. http://dx.doi.org/10.36290/vnl.2017.159.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ettinger, David S., Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 8, no. 7 (July 2010): 740–801. http://dx.doi.org/10.6004/jnccn.2010.0056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ettinger, David S., Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D’Amico, et al. "Non–Small Cell Lung Cancer." Journal of the National Comprehensive Cancer Network 10, no. 10 (October 2012): 1236–71. http://dx.doi.org/10.6004/jnccn.2012.0130.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fromer, Margot J. "Non-Small-Cell Lung Cancer." Oncology Times 30, no. 4 (February 2008): 21–25. http://dx.doi.org/10.1097/01.cot.0000313049.69678.f6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hill, A., P. Fisher, and D. Yeomanson. "Non-small cell lung cancer." BMJ 345, sep27 1 (September 27, 2012): e6443-e6443. http://dx.doi.org/10.1136/bmj.e6443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cox, James D. "Non-small Cell Lung Cancer." Chest 89, no. 4 (April 1986): 284S—288S. http://dx.doi.org/10.1378/chest.89.4_supplement.284s.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Non-small cell lung cancer"

1

Kapeleris, Joanna C. "Circulating tumour cells in non-small cell lung cancer." Thesis, Queensland University of Technology, 2022. https://eprints.qut.edu.au/228607/1/Joanna_Kapeleris_Thesis.pdf.

Full text
Abstract:
Circulating tumour cells (CTCs) have the potential to transform the management of patients with non-small cell lung cancer (NSCLC). The applications of CTCs can identify clinically actionable targets to predict treatment response and to better understand metastasis. CTCs isolated using microfluidics can be used as prognostic indicators of NSCLC as well as characterizing for markers of immunotherapy (PD-L1), molecular targets (ALK, EGFR). Short term cultures were successfully expanded in 9/70 NSCLC patients and cultured for up to 3 months. Optimization of this novel CTC culture model provides opportunity to identify new therapeutics for NSCLC patients in a precision medicine approach.
APA, Harvard, Vancouver, ISO, and other styles
2

Sikkink, Stephen K. "Genetic pathology of non-small cell lung cancer." Thesis, University of Liverpool, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.250405.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wong, Wing-sze, and 黃詠詩. "Fusion genes in non-small cell lung cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B43781378.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Swinson, Daniel. "Hypoxic markers in non-small cell lung cancer." Thesis, University of Leicester, 2004. http://hdl.handle.net/2381/29476.

Full text
Abstract:
Hypoxia is an important factor in the pathogenesis of solid tumours. Hypoxia inducible factors (HIF)-1alpha and HIF-2alpha are transcription factors that in part mediate the cellular response to hypoxia. These transcription factors are involved in the regulation of angiogenesis, anaerobic metabolism, pH homeostasis, erythropoiesis and cell death.;Immunohistochemical (IHC) assays were optimised for HIF-1alpha and one of its transcriptional targets, Carbonic Anhydrase (CA) IX. Attempts to optimise an IHC assay for HIF-2alpha failed to produce reproducible staining. A scoring system was also devised to assess the extent of tumour necrosis (TN) in tumour sections. The expression of these factors was assessed in a retrospective series of patients who had NSCLC tumours resected with curative intent. The expression of EGFR, p53, Bcl-2, MMP-2 and MMP-9 and angiogenesis had previously been assessed.;Extensive TN, perinuclear (p) CA IX and high HIF-1alpha expression were associated with a poor prognosis. PCA IX, stage, gender, MMP-9 and angiogenesis were independent prognostic factors.;The spatial relationship between membranous CA IX expression and TN and tumour microvessels support other studies proposing that CA IX is a marker of tumour hypoxia.;EGFR expression was associated with pCA IX, membranous (m)CA IX and HIF-1alpha expression. In vitro studies demonstrated that prolonged treatment with the EGFR tyrosine kinase inhibitor, ZD 1839 suppressed CA IX expression. These results suggest that activated EGFR may induce CA IX. As such co-expression of these factors may identify patients that are more likely to respond to EGFR targeted therapies.
APA, Harvard, Vancouver, ISO, and other styles
5

Wong, Wing-sze. "Fusion genes in non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B43781378.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Brena, Romulo Martin. "Aberrant DNA methylation in human non-small cell lung cancer." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1172083621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Brattström, Daniel. "Angiogenesis related markers in non-small cell lung cancer /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl.[distributör], 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3558.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Xinarianos, George. "Genetic alterations in non-small cell lung carcinomas." Thesis, University of Liverpool, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.343688.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Brattström, Daniel. "Angiogenesis Related Markers In Non-Small Cell Lung Cancer." Doctoral thesis, Uppsala University, Oncology, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3558.

Full text
Abstract:

This thesis investigated the predictive and the prognostic powers of angiogenesis related markers in both operable and inoperable non-small cell lung cancer (NSCLC) patients.

In the first and second study, we investigated the serological fractions of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in 2 cohorts of patients with either operable or inoperable NSCLC.

Regarding operable NSCLC, we demonstrated significant correlations between VEGF and tumour volume and overall survival. Regarding bFGF, significant correlations with recurrent disease and survival were demonstrated. VEGF and bFGF correlated to each other and with platelet counts. In multivariate analysis, bFGF proved to be a significantly independent prognostic factor.

Regarding inoperable NSCLC, we demonstrated that patients with elevated bFGF levels before any treatment and during chemotherapy had a significantly poorer survival. During chemotherapy, each rise of one unit of bFGF (ng/L) corresponded to a 4 times increased risk of death. Regarding VEGF, elevated levels after radiotherapy corresponded with better survival. All prognostic information demonstrated in this study concerned patients with a, co-sampled, normal platelet count.

In the third study, three putative markers, HER-2, EGFR and COX-2, suitable for targeted therapies in resected NSCLC were investigated in a panel of 53 tumours and further investigated for a possible correlation with microvessel density. We demonstrated that HER-2 and COX-2 were mainly expressed in adenocarcinomas, whereas EGFR was only expressed in squamous cell carcinomas. COX-2 showed a trend towards a correlation with microvesssel density. The expression profile, HER-2+/EGFR-, was significantly correlated to poorer survival.

In the fourth study, a predictive model for recurrences consisting of p53, CD34 and CD105, and circulating serum fractions of VEGF and bFGF, was investigated. The two endothelial markers correlated with each other. CD105 expression correlated with p53 expression. No other significant correlations between markers could be demonstrated. A significant correlation between p53 overexpression and recurrent disease was demonstrated. The mutational status could not confirm the immunohistochemical correlation between p53 and recurrences.

In conclusion, the present thesis demonstrates that the angiogenic factors VEGF and bFGF analysed in sera have both predictive and prognostic information when measured in operable and inoperable NSCLC. Since HER-2 is overexpressed in NSCLC and linked with prognostic information, this marker might be a suitable target for therapy in NSCLC. Furthermore, in patients with operable NSCLC, p53 expression status was linked with recurrent disease and mean MVD.

APA, Harvard, Vancouver, ISO, and other styles
10

Lam, Chi-leung David. "Gene expression profiling in non-small cell lung cancer." Click to view the E-thesis via HKUTO, 2007. http://sunzi.lib.hku.hk/hkuto/record/B38585777.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Non-small cell lung cancer"

1

T, Carr David, and International Cancer Research Data Bank., eds. Non-small cell lung cancer. Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Cancer Institute, International Cancer Research Data Bank, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ramaswamy, Govindan, ed. Locally advanced non-small-cell lung cancer. Manhasset, NY: CMP United Business Media, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Seeber, Siegfried, ed. Small Cell Lung Cancer. Berlin, Heidelberg: Springer Berlin Heidelberg, 1985. http://dx.doi.org/10.1007/978-3-642-82372-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Recent advances in locally advanced non-small-cell lung cancer. Manhasset, N.Y: CMPMedica, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ettinger, David S. The role of chemotherapy in non-small cell lung cancer. Syracuse, NY: Bristol Laboratories Oncology Products, Bristol-Myers Oncology Division, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1935-, Skarin Arthur T., and Alexander Eben, eds. Multimodality treatment of lung cancer. New York: M. Dekker, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jerome, Seidenfeld, Blue Cross and Blue Shield Association. Technology Evaluation Center., and United States. Agency for Healthcare Research and Quality., eds. Management of small cell lung cancer. Rockville, MD: Agency for Healthcare Research and Quality, Public Health Service, U.S. Dept. of Health and Human Services, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Benjamin, Movsas, Langer Corey J, and Goldberg Melvyn, eds. Controversies in lung cancer: A multidisciplinary approach. New York: M. Dekker, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

author, Bujamma D., and M., Naresh Babu (Muppalaneni), author, eds. Bioinformatics of non small cell lung cancer and the ras proto-oncogene. Heidelberg: Springer-Verlag, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Carr, David T. Selected abstracts on small cell lung cancer. Bethesda, MD: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1986.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Non-small cell lung cancer"

1

Munden, Reginald F., and Jeremy J. Erasmus. "Thoracic Imaging Techniques for Non-Small Cell and Small Cell Lung Cancer." In Lung Cancer, 35–56. New York, NY: Springer New York, 2003. http://dx.doi.org/10.1007/0-387-22652-4_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rosell, Rafael, and Delvys Rodriguez-Abreu. "Non-Small-Cell Lung Cancer." In Encyclopedia of Cancer, 1–7. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_4119-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rosell, Rafael, and Delvys Rodriguez-Abreu. "Non-Small-Cell Lung Cancer." In Encyclopedia of Cancer, 3130–35. Berlin, Heidelberg: Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_4119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rosell, Rafael, and Delvys Rodriguez-Abreu. "Non-Small Cell Lung Cancer." In Encyclopedia of Cancer, 2546–51. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_4119.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Hansen, Heine H. "Non-Small Cell Lung Cancer: Staging and Surgery." In Lung Cancer, 30–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76031-0_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hansen, Heine H. "Non-Small Cell Lung Cancer: Radiotherapy and Chemotherapy." In Lung Cancer, 42–43. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-76031-0_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cox, James D., and David J. Stewart. "Chemoradiotherapy for Inoperable Non-small Cell Lung Cancer." In Lung Cancer, 161–75. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-524-8_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wahl, Michael, Matthew A. Gubens, and Sue S. Yom. "Non-small Cell Lung Cancer." In Handbook of Evidence-Based Radiation Oncology, 293–321. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-62642-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Nguyen, Quynh-Nhu, Ritsuko Komaki, Daniel R. Gomez, and Zhongxing Liao. "Non-small Cell Lung Cancer." In Intensity-Modulated Radiation Therapy, 249–60. Tokyo: Springer Japan, 2015. http://dx.doi.org/10.1007/978-4-431-55486-8_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jabbari, Siavash, Eric K. Hansen, and Daphne A. Haas-Kogan. "Non-small Cell Lung Cancer." In Handbook of Evidence-Based Radiation Oncology, 221–47. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-92988-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Non-small cell lung cancer"

1

Patel, Sagar S., Ramesh Natarajan, and Rebecca L. Heise. "Mechanotransduction of Primary Cilia in Lung Adenocarcinoma." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80435.

Full text
Abstract:
Lung cancer causes more than 1 million deaths worldwide annually [1]. In a recent study by the American Cancer Society in 2011, more than 221,000 new cases of lung cancers were reported [2]. Out of these, the mortality rate was found in roughly 70% of the cases [2]. Lung cancer is divided into two major categories: small cell and non-small cell. In the United States, non-small cell lung cancer accounts for 85% of all lung cancers and is considered the most common type of lung cancer [2]. It is usually resistant to chemotherapy, therefore making it extremely difficult to treat [3]. Furthermore adenocarcinomas, a type of non-small cell lung cancer, occur towards the periphery of the lungs and are the most common type accounting for 40–45% of all lung cancer cases [3]. Epithelial cells in the healthy lungs undergo stresses during inhalation and expiration of normal breathing. In addition to the forces of normal breathing, lung cancer cells may also experience abnormal mechanical forces due to pre-existing lung diseases such as asthma, bronchitis and chronic obstructive pulmonary disease or other tumor associated structural changes. These conditions can significantly alter the structure of the lungs and cell phenotype [4]. The change in the structure of the lungs affects the mechanical environment of the cells. Changes in extracellular (ECM) stiffness, cell stretch, and shear stress influence tumorigenesis and metastasis [5]. One mechanism through which the cells sense and respond to the cellular mechanical environment is through the primary cilia [6–7]. Primary cilia are non-motile, solitary structures formed from the cellular microtubules and protrude out of each cell. They have also been shown to play an important role in facilitating common cancer signaling pathways such as Sonic Hedgehog and Wnt/β-catenin signaling [8–9]. The objective of this study was to test the hypothesis that lung cancer cells respond to mechanical stimuli with the formation of primary cilia that are necessary for 3 hallmarks of tumor progression: proliferation, epithelial mesenchymal-transition, and migration.
APA, Harvard, Vancouver, ISO, and other styles
2

Gileva, M. S., E. G. Ufimceva, L. F. Gulyaeva, and V. V. Kozlov. "EX VIVO CHARACTERISTICS OF NON-SMALL CELL LUNG CANCER CELLS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-308.

Full text
Abstract:
The search for molecular markers for the identification of adenocarcinoma and squamous cell lung cancer remains an urgent problem. In this work, for the first time, an ex vivo method was used to isolate cells from tissue samples of patients with non-small cell lung cancer. Potential markers of this histological tumor type were analyzed, and the cellular composition of the immune microenvironment was also assessed, including depending on the smoking status of patients.
APA, Harvard, Vancouver, ISO, and other styles
3

Benammar, Sarra, Fatima Mraiche, Jensa Mariam Joseph, and Katerina Gorachinova. "Glucose and Transferrin Liganded PLGA Nanoparticles Internalization in Non-Small Lung Cancer Cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2020. http://dx.doi.org/10.29117/quarfe.2020.0227.

Full text
Abstract:
Introduction: Recently, after a decade of confusing results, several studies pointed out that overexpression of GLUT1 (glucose transporter 1) is a biomarker of worse prognosis in NSCLC. Nonetheless, the presence of transferrin (Tf receptor), which is overexpressed in most cancer tissues and most lung cancers as well, in NSCLC is also an indicator of very poor prognosis. Therefore, these ligands can be used for active targeting of lung cancer cells and improved efficacy of internalization of cancer therapy using nanomedicines. Objectives: Having the background, the main goal of the project was the assessment of the influence of the glucose and transferrin ligands on the efficacy of internalization of the designed (i) glucose decorated PLGA (poly lactic-coglycolic acid) nanoparticles (Glu-PLGA NPs) and (ii) transferrin decorated PLGA nanoparticles (Tf-PLGA NPs) in comparison to (iii) non-liganded PLGA NPs using a A549 lung cancer cells. Methods: Glu-PLGA NPs, Tf-PLGA NPs and PLGA NP - fluorescently labelled), were designed using a sonication assisted nanoprecipitation method. Further, physicochemical properties characterization (particle size analysis, zeta potential, FTIR analysis, DSC analysis), cytotoxicity evaluation using MTT test, and cell internalization studies of DTAF labelled NPs using fluorimetry in A549 NSCLC cell line were performed. Results: The results pointed to a significantly improved internalization rate of the liganded compared to PLGA NPs. Glu-PLGA NPs showed higher internalization rate compared to Tf-PLGA and PLGA NPs, in the serum-supplemented and serumfree medium even at normal levels of glucose in the cell growth medium. Conclusion: The developed nanocarriers offer unique advantages of enhanced targetability, improved cell internalization and decreased toxicity, which makes them promising solution for current therapeutic limitations.
APA, Harvard, Vancouver, ISO, and other styles
4

Xing, Fuyong, and Lin Yang. "Robust cell segmentation for non-small cell lung cancer." In 2013 IEEE 10th International Symposium on Biomedical Imaging (ISBI 2013). IEEE, 2013. http://dx.doi.org/10.1109/isbi.2013.6556493.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dias, Margarida, Raquel Marçoa, Rita Linhas, Sérgio Campainha, Sara Conde, and Ana Barroso. "Non-small cell lung cancer in never-smokers." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2796.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Neffati, O., L. Fekih, H. Kammoun, A. Ayari, I. Mejri, H. Smadhi, I. Akrout, et al. "Prognostic factors in non-small cell lung cancer." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa4294.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Fu, Pin-Kuei. "Octogenarians With Operable Non-Small Cell Lung Cancer." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4407.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Hamedi, Z., S. Kamboj, S. Kumar, R. A. Jiwani, and N. Sharma. "Transformation of Non-Small Cell Lung Cancer (NSCLC) to Small Cell Lung Cancer (SCLC), Mechanism of Treatment Resistance?" In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4871.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Paschoal, Marcos Eduardo M., Teresa C. F. Santos, Nathalie H. S. Canedo, Paulo M. N. Valiante, Heitor S. P. Souza, Mauro S. G. Pavao, and Morgana T. L. Castelo Branco. "Heparanase 1 Expression In Non-Small Cell Lung Cancer." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6373.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cruz, Carla, André Rico, Fani Sousa, Bernardo Teixeira, and Daniela Alexandre. "miRNA Detection for non-small cell lung cancer diagnosis." In 7th International Electronic Conference on Medicinal Chemistry. Basel, Switzerland: MDPI, 2021. http://dx.doi.org/10.3390/ecmc2021-11506.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Non-small cell lung cancer"

1

Freire, Mariana, Diana Martins, Maria Filomena Botelho, and Fernando Mendes. Biomarkers of resistance mechanisms in innovative lung cancer treatments - A systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0011.

Full text
Abstract:
Review question / Objective: This systematic review aims to provide an overview of the immunotherapy resistance mechanisms and identify potential biomarkers associated with immunotherapy response in NSCLC, as well as examine new treatment options to overcome this hurdle. Condition being studied: Lung Cancer (LC) remains one of the leading cancers worldwide. In 2020, were globally estimated 2 206 771 new cases and 1 796 144 deaths, representing the uttermost frequent cause of cancer death. LC is classified histologically into small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC), being the last one the most common, representing 80 to 85% of all LC. The three predominantly subtypes of NSCLC are lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC) and large cell carcinoma (LCLC). NSCLC is usually diagnosed in advanced-staged disease due to ambiguous and delayed severe symptoms.
APA, Harvard, Vancouver, ISO, and other styles
2

Watson, Mark A. Genomic Characterization of Brain Metastasis in Non-Small Cell Lung Cancer Patients. Fort Belvoir, VA: Defense Technical Information Center, January 2014. http://dx.doi.org/10.21236/ada606182.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kang, Jing, Jun Zhang, Zongsheng Tian, Ye Xu, Jiangbi Li, and Mingxina Li. The efficacy and safety of immune-checkpoint inhibitor plus chemotherapy versus chemotherapy for non-small cell lung cancer: an updated systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0156.

Full text
Abstract:
Review question / Objective: Population: histologically confirmed advanced NSCLC patients; Intervention: received immune-checkpoint inhibitor plus chemotherapy; Comparison:received chemotherapy; Outcome: reported OS, PFS, ORR and TRAEs; Study design: RCT. Condition being studied: Lung cancer is the primary cause of cancer-related deaths, with an estimated 2.20 million new cases and 1.79 million deaths every year, and 85% of all primary lung cancers are non-small cell lung cancer. Eligibility criteria: Studies were considered eligible if they met the following criteria: (1) being an randomized controlled trial published in English, (2) histologically confirmed advanced NSCLC patients, (3) reported OS, PFS, ORR and TRAEs, (4) the intervention group received immune-checkpoint inhibitor plus chemotherapy, while the control group received chemotherapy, (5) When numerous papers reporting the same trial were found, the most current or most complete publications were chosen. The following were the exclusion criteria: (1) duplicate articles, (2) reviews, meta-analyses, case reports, editorials and letters, (3) molecular biology or animal research, (4) retrospective or prospective observational cohort studies.
APA, Harvard, Vancouver, ISO, and other styles
4

Nelkin, Barry D. Role of CDK5 as a Tumor Suppressor Gene in Non-Small Cell Lung Cancer. Fort Belvoir, VA: Defense Technical Information Center, August 2014. http://dx.doi.org/10.21236/ada610950.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Li, Yong, Fang Yang, and Ya-Yong Huang. Sublobar resection versus ablation for stage I non-small-cell lung cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2021. http://dx.doi.org/10.37766/inplasy2021.1.0075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Zhong-Ke, and Yuan-Shun Xu. I-125 seeds with chemotherapy for progressive non-small-cell lung cancer after first-line treatment. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2021. http://dx.doi.org/10.37766/inplasy2021.10.0120.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Peng, Yinglong, Jinwei Chen, Ziyan Wang, Yihui Cao, and Jie Zhao. A Systematic Review and meta-analysis of the efficacy of immunotherapy in the treatment of non-small cell lung cancer. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, June 2022. http://dx.doi.org/10.37766/inplasy2022.6.0094.

Full text
Abstract:
Review question / Objective: This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection of different regimens. Condition being studied: Immunotherapy is a relatively new treatment method for non-small cell lung cancer (NSCLC), and clinical studies confirmed that immune checkpoint inhibitors (ICIs) showed prominent efficacy in the treatment of NSCLC patients. This study aimed to compare the effectiveness of different ICIs in the treatment of NSCLC, and to provide a theoretical basis for clinical selection of different regimens.
APA, Harvard, Vancouver, ISO, and other styles
8

Peng, Ciyan, Jing Chen, Sini Li, and Jianhe Li. Comparative Efficacy of Chinese Herbal Injections Combined Western medicine for Non-small cell lung cancer: A Bayesian Network Meta-Analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0068.

Full text
Abstract:
Review question / Objective: Advanced lung cancer has become the top malignant tumor in terms of morbidity and mortality, and Chinese herbal injections combined with western drugs have been widely used to treat advanced non-small cell lung cancer. For this purpose, we conducted a Bayesian network analysis to systematically evaluate the efficacy of different herbal injections combined with western drugs in the treatment of NSCLC. Subjects: Patients diagnosed with NSCLC by pathological or cytological examination, locally advanced or those who refused surgical treatment were included, regardless of gender, age, stage, race, nationality and sample size; Interventions: Chinese herbal injections combined with three types of commonly used western drugs (platinum, targeted and immune agents) were used in the experimental group, while the control group was treated with western drugs alone; Study type: to report the efficacy of Chinese herbal injections combined with western drugs in the treatment of non-small cell lung cancer efficacy in a randomized controlled trial (rct) Eligible. No restrictions were imposed on language, year of publication, or publication status. Ending indicators: Main ending indicators: (1) disease control rate (DCR), DCR = (complete remission + partial remission + stable)/total number of cases. Efficacy rate = (number of improvement cases + number of stable cases)/total number of cases. (2) Secondary outcome indicators: quality of life, determined according to the KPS behavioral status scale, improvement was defined as an increase of ≥10 points in KPS score after treatment; stability was defined as an increase or decrease of <10 points in KPS score; decline was defined as a decrease of ≥10 points in KPS score. (3) The incidence of adverse reactions, including gastrointestinal reactions, white blood cell (WBC) reduction, hemoglobin (HGB) reduction, platelet (PLT) reduction, etc.
APA, Harvard, Vancouver, ISO, and other styles
9

Tong, Zhangwei, Fei Luo, Xiaojie Yang, and Jiangbo Lin. Platinum vs immunotherapy for early resectable non-small cell lung cancer: a systematic review and meta-analysis protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2020. http://dx.doi.org/10.37766/inplasy2020.8.0064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shi, Yucong, Ziqi Chen, Sizhi Wu, Yiwen Lv, Pei Liu, Huachong Xu, Li Deng, and Xiaoyin Chen. Comparison of Segmentectomy, Lobectomy and Wedge Resection for Early-stage Non-Small Cell Lung Cancer: A Bayesian analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2020. http://dx.doi.org/10.37766/inplasy2020.8.0090.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Non-small cell lung cancer' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography